Breaking News, Promotions & Moves

Hansa Biopharma Names Hitto Kaufmann Chief Scientific Officer

Kaufmann will be responsible for research, early development, translational and manufacturing activities.

Hansa Biopharma, a company involved in enzyme technology for rare immunological conditions, appointed Hitto Kaufmann chief scientific officer (CSO) effective December 1, 2023. Kaufmann will be responsible for all research, early development, translational and manufacturing activities. He will report to President & CEO Søren Tulstrup and serve as a member of Hansa’s executive committee. Kaufmann joins Hansa from Pieris Pharmaceuticals where he has served as chief scientific officer sinc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters